|Previous Section||Index||Home Page|
Ms Blears [holding answer 4 July 2002]: I refer the hon. Member to the answer the then Parliamentary Under-Secretary of State for Health my hon. Friend the Member for Pontefract and Castleford (Yvette Cooper) gave him on 11 June 2002, Official Report, column 1212W.
Ms Blears [holding answer 4 July 2002]: Copaxone (glatiramer acetate) is available on the national health service under the "risk-sharing scheme" for disease- modifying drugs for multiple sclerosis that came into operation on 6 May 2002.
10 Jul 2002 : Column 1046W
Ms Blears [holding answer 4 July 2002]: It is a general legal and ethical requirement for a health professional to seek consent before starting to treat or examine a patient, which would include the obtaining of deoxyribonucleic acid (DNA) samples. The position is laid out clearly in the Department's reference guide to consent for treatment and examination.
There are exceptions to the principle of consent for certain uses of DNA samples, for example the obtaining of non-intimate DNA samples by the police for use in the prevention, detection or investigation of a crime.
The human genetics commission's report "Inside Information" has recommended a new criminal offence of the non-consensual or deceitful obtaining or analysis of genetic information for non-medical purposes. The Government are still considering this report and will respond in due course.
Mr. David Stewart: To ask the Secretary of State for Health when he expects to receive guidance from the National Institute for Clinical Excellence on the use of photodynamic therapy for age-related macular degeneration. 
Ms Blears [holding answer 4 July 2002]: The National Institute for Clinical Excellence published its final appraisal determination on photodynamic therapy on 12 June. This has been appealed against. An appeal panel will now be convened to hear the appeal and decide the outcome. If the appeal is not upheld then guidance will be published; however, if it is upheld, then the appeals panel will ask the appraisal committee to reconsider the evidence in light of the appeal panel's decision. The earliest guidance could be available to the national health service is early August.
Mr. Hutton: "Improving Working Lives" (IWL) is an integral part of the human resources performance management process within the national health service. Existing NHS organisations are required to achieve "Practice" stage of the standard by April 2003, and the target for new organisations is April 2004.
Ms Blears [holding answer 10 July 2002]: PC SPES has not been licensed as a medicinal product in the United Kingdom. However, I understand that it has been recalled by its American manufacturers as it has been found to contain undeclared prescription drug ingredients. The four research studies into its effectiveness that are being
10 Jul 2002 : Column 1047W
Bob Spink: To ask the Secretary of State for Health what the recommendations of the report, "Feet First Two", are regarding (a) removal of regional and local variations in service provisions and (b) improving the availability of services in the south of England. 
Jacqui Smith: We currently have no plans to publish any findings from the review of "Feet First". In April 2001, my right hon. Friend the Minister of State made a statement about the review in his response to a question from the hon. Member for Hazel Grove (Mr. Stunell). I refer the hon. Member to the reply given on 10 April 2002, Official Report, column 604W.
Mr. Dobson: To ask the Secretary of State for Health what proportion of appointments to health trusts and authorities by the NHS Appointments Commission have been (a) women and (b) black or Asian. 
Mr. Hutton: The latest figures available (for April 2002) show that since the National Health Service Appointments Commission was established, 44.6 per cent. of appointments made to NHS boards have been women, and 8.9 per cent. from black and ethnic minority communities.
10 Jul 2002 : Column 1048W
Ms Blears: There were 362 HIV/AIDS-related deaths in 2001 reported in the United Kingdom by the end of March 2002. This total, which includes deaths in HIV-infected individuals without reported AIDS, is likely to rise as late reports are received.
Mr. Lammy: The only cost data currently collected centrally on diabetes relate to treatments undertaken by National Health Service Trusts. These exclude costs for diabetes within general practice and other primary care settings. Costs in the financial year 200001 are shown in the table. Comparable data are not available for earlier years.
|Elective in-patients||Non-elective in-patients||Day case patients|
|Number||Unit cost (£)||Number||Unit cost (£)||Number||Unit cost (£)|
|Diabetes with hypoglycaemic emergency (aged more than 69 or with co-morbidities)||48||1,395||3,027||954||10||222|
|Diabetes with hypoglycaemic emergency (aged less than 70 or without co-morbidities)||198||796||2,406||567||97||352|
|Diabetes with hyperglycaemic emergency (aged more than 69 or with co-morbidities)||22||1,808||3,164||1,126||4||253|
|Diabetes with hyperglycaemic emergency (aged less than 70 or without co-morbidities)||26||1,024||6,072||659||9||261|
|Diabetes with other hyperglycaemic disorder (aged more than 69 or with co-morbidities)||392||1,534||7,132||1,288||946||224|
|Diabetes with other hyperglycaemic disorder (aged less than 70 or without co-morbidities)||389||871||6,250||686||2,503||274|
|Diabetes with lower limb complications||523||2,183||5,280||1,726||82||323|
Reference Costs 2001published on the Department of Health website at www.doh.gov.uk/nhsexec/refcosts.htm.
10 Jul 2002 : Column 1049W
Mr. Lammy: Funding for diabetes is being considered as part of the current Government spending review, together with other priorities. The Budget provides the highest sustained growth in national health service history with annual average increases of 7.4 per cent. in real terms over the five years 200304 to 200708. Decisions about the allocation of the increased funding will be announced later this year.
Mr. Lammy: There is a well established association between diabetes and coronary heart disease. There are a number of common risk factors. In particular, people who are overweight or obese, those who are not physically active and those who do not enjoy a balanced diet are at greater risk of both Type 2 diabetes and coronary heart disease. The standards for the diabetes national service framework, published in December 2001, highlight the importance of common strategies for prevention and treatment. In doing so, they build on the frameworks for coronary heart disease and older people.
|Year||Diagnosed prevalence||Total patients (million)|
Mr. Pickthall: To ask the Secretary of State for Health what his Department's estimate is of (a) the number of patients awaiting diagnosis for diabetes and (b) the percentage of newly diagnosed diabetics who show signs of complications. 
Mr. Lammy: Estimates of the number of people awaiting diagnosis for diabetes vary depending on which study is consulted. The Department has based its estimates upon the health surveys for England. Extrapolation from the 1993 survey, the largest and most representative study on this question, leads to an estimate of around 550,000 people currently with undiagnosed diabetes. However, other smaller studies suggest that the number could be greater.
10 Jul 2002 : Column 1050W
|Next Section||Index||Home Page|